OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial - Diener, HC; Dodick, DW; Aurora, SK; Turkel, CC; DeGryse, RE; Lipton, RB; Silberstein, SD; Brin, MF; PREEMPT 2 Chronic Migraine Study Group (Cephalalgia, 2010)